Entry Point Capital, LLC Roivant Sciences Ltd. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Entry Point Capital, LLC holds 1,148 shares of ROIV stock, worth $13,500. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,148Holding current value
$13,500% of portfolio
0.02%Shares
2 transactions
Others Institutions Holding ROIV
# of Institutions
314Shares Held
495MCall Options Held
1.29MPut Options Held
1.15M-
Sb Investment Advisers (Uk) LTD London, X071.4MShares$839 Million6.97% of portfolio
-
Viking Global Investors LP69.2MShares$813 Million2.91% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$785 Million72.99% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$416 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.3MShares$345 Million0.02% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.28B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...